Press coverage about Intra-Cellular Therapies (NASDAQ:ITCI) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intra-Cellular Therapies earned a news impact score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.4664246108822 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Intra Cellular Therapies : Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for Neuroscience Annual Meeting (4-traders.com)
- Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for … – GlobeNewswire (press release) (globenewswire.com)
- Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for Neuroscience (SfN) Annual Meeting (finance.yahoo.com)
- Intra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr. Andrew Satlin as Executive Vice President and Chief Medical Officer (finance.yahoo.com)
- FY2017 EPS Estimates for Intra-Cellular Therapies Inc. Raised by Leerink Swann (ITCI) (americanbankingnews.com)
ITCI has been the topic of a number of recent analyst reports. Cowen and Company reaffirmed a “buy” rating and set a $20.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, August 23rd. Cantor Fitzgerald reissued a “buy” rating on shares of Intra-Cellular Therapies in a report on Wednesday, August 9th. Piper Jaffray Companies raised Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and upped their target price for the company from $14.00 to $33.00 in a report on Thursday, September 7th. SunTrust Banks, Inc. raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Wednesday, November 8th. Finally, JMP Securities raised Intra-Cellular Therapies from a “market perform” rating to an “outperform” rating and set a $24.00 target price on the stock in a report on Thursday, August 24th. Two analysts have rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $25.00.
Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.53). Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.06 million. During the same period in the prior year, the business earned ($0.70) earnings per share. The business’s revenue was up 675.0% on a year-over-year basis. sell-side analysts anticipate that Intra-Cellular Therapies will post -2.16 EPS for the current fiscal year.
In related news, major shareholder Alafi Capital Co Llc acquired 258,065 shares of Intra-Cellular Therapies stock in a transaction dated Monday, October 2nd. The shares were acquired at an average cost of $15.50 per share, for a total transaction of $4,000,007.50. Following the completion of the transaction, the insider now directly owns 3,953,270 shares of the company’s stock, valued at $61,275,685. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Sharon Mates sold 18,750 shares of the company’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $15.75, for a total value of $295,312.50. Following the completion of the sale, the chief executive officer now owns 1,107,457 shares in the company, valued at $17,442,447.75. The disclosure for this sale can be found here. 19.80% of the stock is owned by corporate insiders.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.